Feng Li

US Patent:

7537765, May 26, 2009

Filed:

May 24, 2004

Appl. No.:

10/851637

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

Panacos Pharmaceuticals, Inc. - Gaithersburg MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/21
A61K 38/00

US Classification:

4241841, 530300, 4241861, 4241871, 4241881

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

8318425, Nov 27, 2012

Filed:

Jul 6, 2009

Appl. No.:

12/498157

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Brookings SD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department & Human Services - Washington DC
Myrexis, Inc. - Salt Lake City UT

International Classification:

C12Q 1/70
C12Q 1/68
A01N 61/00
A01N 57/00
A61K 31/00
A61K 31/66

US Classification:

435 61, 435 5, 435 611, 435 612, 514 1, 514120, 514510

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20040219166, Nov 4, 2004

Filed:

Jul 24, 2003

Appl. No.:

10/627568

Inventors:

Ronald Montelaro - Wexford PA, US
Jodi Craigo - Allian Park PA, US
Feng Li - Gaithersburg MD, US

International Classification:

A61K048/00
A61K039/12
C12N007/00

US Classification:

424/199100, 424/093200, 435/235100

Abstract:

The invention provides an equine infectious anemia (EIA) vaccine and/or construct that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which, in embodiments, allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. In various embodiments, said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

US Patent:

20040265320, Dec 30, 2004

Filed:

Jan 29, 2004

Appl. No.:

10/766528

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl Wild - Gaithersburg MD, US
Graham Allaway - Darnestown MD, US
Eric Freed - Frederick MD, US

International Classification:

A61K039/42

US Classification:

424/160100

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080200550, Aug 21, 2008

Filed:

May 24, 2005

Appl. No.:

11/597431

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

V.I. TECHNOLOGIES, INC. - Gaithersburg MD
THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTH - Rockville MD

International Classification:

A61K 31/557

US Classification:

514573

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080233559, Sep 25, 2008

Filed:

Dec 21, 2007

Appl. No.:

11/962315

Inventors:

Karl SALZWEDEL - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20210226054, Jul 22, 2021

Filed:

Apr 7, 2021

Appl. No.:

17/224171

Inventors:

- Austin TX, US
Feng Li - Austin TX, US
Vishnu Khemka - Chandler AZ, US
Moaniss Zitouni - Gilbert AZ, US
Tanuj Saxena - Chandler AZ, US

International Classification:

H01L 29/78
H01L 21/8234
H01L 27/088
H01L 29/10
H01L 29/66

Abstract:

A MOSFET includes a substrate having a body region of a first conductivity type. A main field effect transistor (mainFET) and a mirror device are formed in the substrate. The mainFET includes first gate trenches, first source regions of a second conductivity type adjacent to the first gate trenches, and first body implant regions of the first conductivity type extending into the body region adjacent to and interposed between the first source regions. The mirror device includes second gate trenches, second source regions of the second conductivity type adjacent to the second gate trenches, second body implant regions of the first conductivity type extending into the body region adjacent to and interposed between the second source regions, and link elements of the first conductivity type interconnecting pairs of the second body implant regions.

US Patent:

20200373426, Nov 26, 2020

Filed:

May 20, 2019

Appl. No.:

16/417243

Inventors:

- Austin TX, US
Feng Li - Austin TX, US
Vishnu Khemka - Chandler AZ, US
Moaniss Zitouni - Gilbert AZ, US
Tanuj Saxena - Chandler AZ, US

International Classification:

H01L 29/78
H01L 27/088
H01L 29/10
H01L 29/66
H01L 21/8234

Abstract:

A MOSFET includes a substrate having a body region of a first conductivity type. A main field effect transistor (mainFET) and a mirror device are formed in the substrate. The mainFET includes first gate trenches, first source regions of a second conductivity type adjacent to the first gate trenches, and first body implant regions of the first conductivity type extending into the body region adjacent to and interposed between the first source regions. The mirror device includes second gate trenches, second source regions of the second conductivity type adjacent to the second gate trenches, second body implant regions of the first conductivity type extending into the body region adjacent to and interposed between the second source regions, and link elements of the first conductivity type interconnecting pairs of the second body implant regions.